Global Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer Comprehensive Study by Treatment (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), End-users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), Diagnosis (CT Scan, MRI, PET, Ultrasound, Biopsy, Others) Players and Region - Global Market Outlook to 2030

Hormone Refractory Prostate Cancer Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.64%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Hormone Refractory Prostate Cancer Market Scope
Hormone-refractory prostate cancer treatment options include secondary hormonal manipulations, chemotherapy, experimental options, and best supportive care. Hormone refractory prostate cancer is a peculiar type of cancer that relapses even after hormonal therapy. It recurs after having hormonal therapy treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbVie Inc. (United States), Acceleron Pharma Inc. (United States), AB Science SA (France), AstraZeneca Plc. (United Kingdom), Astellas Pharma Inc. (Japan), Boston Biomedical, Inc. (United States), Dendreon Corporation (United States), Sanofi S.A (France) and Johnson & Johnson (United States)
CAGR9.64%


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Hormone Refractory Prostate Cancer market throughout the predicted period.

AbbVie Inc. (United States), Acceleron Pharma Inc. (United States), AB Science SA (France), AstraZeneca Plc. (United Kingdom), Astellas Pharma Inc. (Japan), Boston Biomedical, Inc. (United States), Dendreon Corporation (United States), Sanofi S.A (France) and Johnson & Johnson (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Hormone Refractory Prostate Cancer market by Type and Region with country level break-up.

On the basis of geography, the market of Hormone Refractory Prostate Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In September 2023, Bayer acquired Noria Therapeutics and PSMA Therapeutics in 2021, gaining access to promising investigational drugs targeting PSMA-positive prostate cancer, including HRPCA. The company is actively developing these drugs and expects to initiate clinical trials shortly.
In October 2023, J&J remains a major player with Zytiga, another established androgen receptor signaling inhibitor for HRPCA. The company is currently focusing on expanding access programs and conducting research to explore potential combination therapies involving Zytiga.


Influencing Trend:
Increased Demand for Advanced Treatment for Cancers and Growing Investments in Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Prostate Cancer and Rise in the Number of Hospitals and Clinics

Challenges:
Stringent Government Rules and Regulations

Restraints:
Recurrence of the Prostate Cancer

Opportunities:
Growth in the Healthcare Industry Worldwide and Increased Government Initiatives for Cancer Research and Development

Key Target Audience
Pharmaceutical Companies, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Treatment
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery

By End-users
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Diagnosis
  • CT Scan
  • MRI
  • PET
  • Ultrasound
  • Biopsy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Prostate Cancer
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Demand for Advanced Treatment for Cancers
      • 3.4.2. Growing Investments in Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormone Refractory Prostate Cancer, by Treatment, End-users, Distribution Channel, Diagnosis and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hormone Refractory Prostate Cancer (Value)
      • 5.2.1. Global Hormone Refractory Prostate Cancer by: Treatment (Value)
        • 5.2.1.1. Chemotherapy
        • 5.2.1.2. Hormonal Therapy
        • 5.2.1.3. Immunotherapy
        • 5.2.1.4. Radiation Therapy
        • 5.2.1.5. Surgery
      • 5.2.2. Global Hormone Refractory Prostate Cancer by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Specialty Clinics
      • 5.2.3. Global Hormone Refractory Prostate Cancer by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Others
      • 5.2.4. Global Hormone Refractory Prostate Cancer by: Diagnosis (Value)
        • 5.2.4.1. CT Scan
        • 5.2.4.2. MRI
        • 5.2.4.3. PET
        • 5.2.4.4. Ultrasound
        • 5.2.4.5. Biopsy
        • 5.2.4.6. Others
      • 5.2.5. Global Hormone Refractory Prostate Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hormone Refractory Prostate Cancer (Price)
  • 6. Hormone Refractory Prostate Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Acceleron Pharma Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AB Science SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca Plc. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boston Biomedical, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dendreon Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi S.A (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Hormone Refractory Prostate Cancer Sale, by Treatment, End-users, Distribution Channel, Diagnosis and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hormone Refractory Prostate Cancer (Value)
      • 7.2.1. Global Hormone Refractory Prostate Cancer by: Treatment (Value)
        • 7.2.1.1. Chemotherapy
        • 7.2.1.2. Hormonal Therapy
        • 7.2.1.3. Immunotherapy
        • 7.2.1.4. Radiation Therapy
        • 7.2.1.5. Surgery
      • 7.2.2. Global Hormone Refractory Prostate Cancer by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Specialty Clinics
      • 7.2.3. Global Hormone Refractory Prostate Cancer by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Others
      • 7.2.4. Global Hormone Refractory Prostate Cancer by: Diagnosis (Value)
        • 7.2.4.1. CT Scan
        • 7.2.4.2. MRI
        • 7.2.4.3. PET
        • 7.2.4.4. Ultrasound
        • 7.2.4.5. Biopsy
        • 7.2.4.6. Others
      • 7.2.5. Global Hormone Refractory Prostate Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hormone Refractory Prostate Cancer (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormone Refractory Prostate Cancer: by Treatment(USD Million)
  • Table 2. Hormone Refractory Prostate Cancer Chemotherapy , by Region USD Million (2018-2023)
  • Table 3. Hormone Refractory Prostate Cancer Hormonal Therapy , by Region USD Million (2018-2023)
  • Table 4. Hormone Refractory Prostate Cancer Immunotherapy , by Region USD Million (2018-2023)
  • Table 5. Hormone Refractory Prostate Cancer Radiation Therapy , by Region USD Million (2018-2023)
  • Table 6. Hormone Refractory Prostate Cancer Surgery , by Region USD Million (2018-2023)
  • Table 7. Hormone Refractory Prostate Cancer: by End-users(USD Million)
  • Table 8. Hormone Refractory Prostate Cancer Hospitals , by Region USD Million (2018-2023)
  • Table 9. Hormone Refractory Prostate Cancer Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 10. Hormone Refractory Prostate Cancer Specialty Clinics , by Region USD Million (2018-2023)
  • Table 11. Hormone Refractory Prostate Cancer: by Distribution Channel(USD Million)
  • Table 12. Hormone Refractory Prostate Cancer Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Hormone Refractory Prostate Cancer Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Hormone Refractory Prostate Cancer Others , by Region USD Million (2018-2023)
  • Table 15. Hormone Refractory Prostate Cancer: by Diagnosis(USD Million)
  • Table 16. Hormone Refractory Prostate Cancer CT Scan , by Region USD Million (2018-2023)
  • Table 17. Hormone Refractory Prostate Cancer MRI , by Region USD Million (2018-2023)
  • Table 18. Hormone Refractory Prostate Cancer PET , by Region USD Million (2018-2023)
  • Table 19. Hormone Refractory Prostate Cancer Ultrasound , by Region USD Million (2018-2023)
  • Table 20. Hormone Refractory Prostate Cancer Biopsy , by Region USD Million (2018-2023)
  • Table 21. Hormone Refractory Prostate Cancer Others , by Region USD Million (2018-2023)
  • Table 22. South America Hormone Refractory Prostate Cancer, by Country USD Million (2018-2023)
  • Table 23. South America Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 24. South America Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 25. South America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 26. South America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 27. Brazil Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 28. Brazil Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 29. Brazil Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 30. Brazil Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 31. Argentina Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 32. Argentina Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 33. Argentina Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 34. Argentina Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 35. Rest of South America Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 36. Rest of South America Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 37. Rest of South America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of South America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 39. Asia Pacific Hormone Refractory Prostate Cancer, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 41. Asia Pacific Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 42. Asia Pacific Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 43. Asia Pacific Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 44. China Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 45. China Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 46. China Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 47. China Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 48. Japan Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 49. Japan Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 50. Japan Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 51. Japan Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 52. India Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 53. India Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 54. India Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 55. India Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 56. South Korea Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 57. South Korea Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 58. South Korea Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 59. South Korea Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 60. Taiwan Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 61. Taiwan Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 62. Taiwan Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 63. Taiwan Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 64. Australia Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 65. Australia Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 66. Australia Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 67. Australia Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 72. Europe Hormone Refractory Prostate Cancer, by Country USD Million (2018-2023)
  • Table 73. Europe Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 74. Europe Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 75. Europe Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 76. Europe Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 77. Germany Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 78. Germany Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 79. Germany Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 80. Germany Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 81. France Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 82. France Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 83. France Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 84. France Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 85. Italy Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 86. Italy Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 87. Italy Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 88. Italy Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 89. United Kingdom Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 90. United Kingdom Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 91. United Kingdom Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 92. United Kingdom Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 93. Netherlands Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 94. Netherlands Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 95. Netherlands Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 96. Netherlands Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 97. Rest of Europe Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 98. Rest of Europe Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 99. Rest of Europe Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 100. Rest of Europe Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 101. MEA Hormone Refractory Prostate Cancer, by Country USD Million (2018-2023)
  • Table 102. MEA Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 103. MEA Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 104. MEA Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 105. MEA Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 106. Middle East Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 107. Middle East Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 108. Middle East Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 109. Middle East Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 110. Africa Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 111. Africa Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 112. Africa Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 113. Africa Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 114. North America Hormone Refractory Prostate Cancer, by Country USD Million (2018-2023)
  • Table 115. North America Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 116. North America Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 117. North America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 118. North America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 119. United States Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 120. United States Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 121. United States Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 122. United States Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 123. Canada Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 124. Canada Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 125. Canada Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 126. Canada Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 127. Mexico Hormone Refractory Prostate Cancer, by Treatment USD Million (2018-2023)
  • Table 128. Mexico Hormone Refractory Prostate Cancer, by End-users USD Million (2018-2023)
  • Table 129. Mexico Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2018-2023)
  • Table 130. Mexico Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2018-2023)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Hormone Refractory Prostate Cancer: by Treatment(USD Million)
  • Table 141. Hormone Refractory Prostate Cancer Chemotherapy , by Region USD Million (2025-2030)
  • Table 142. Hormone Refractory Prostate Cancer Hormonal Therapy , by Region USD Million (2025-2030)
  • Table 143. Hormone Refractory Prostate Cancer Immunotherapy , by Region USD Million (2025-2030)
  • Table 144. Hormone Refractory Prostate Cancer Radiation Therapy , by Region USD Million (2025-2030)
  • Table 145. Hormone Refractory Prostate Cancer Surgery , by Region USD Million (2025-2030)
  • Table 146. Hormone Refractory Prostate Cancer: by End-users(USD Million)
  • Table 147. Hormone Refractory Prostate Cancer Hospitals , by Region USD Million (2025-2030)
  • Table 148. Hormone Refractory Prostate Cancer Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 149. Hormone Refractory Prostate Cancer Specialty Clinics , by Region USD Million (2025-2030)
  • Table 150. Hormone Refractory Prostate Cancer: by Distribution Channel(USD Million)
  • Table 151. Hormone Refractory Prostate Cancer Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 152. Hormone Refractory Prostate Cancer Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 153. Hormone Refractory Prostate Cancer Others , by Region USD Million (2025-2030)
  • Table 154. Hormone Refractory Prostate Cancer: by Diagnosis(USD Million)
  • Table 155. Hormone Refractory Prostate Cancer CT Scan , by Region USD Million (2025-2030)
  • Table 156. Hormone Refractory Prostate Cancer MRI , by Region USD Million (2025-2030)
  • Table 157. Hormone Refractory Prostate Cancer PET , by Region USD Million (2025-2030)
  • Table 158. Hormone Refractory Prostate Cancer Ultrasound , by Region USD Million (2025-2030)
  • Table 159. Hormone Refractory Prostate Cancer Biopsy , by Region USD Million (2025-2030)
  • Table 160. Hormone Refractory Prostate Cancer Others , by Region USD Million (2025-2030)
  • Table 161. South America Hormone Refractory Prostate Cancer, by Country USD Million (2025-2030)
  • Table 162. South America Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 163. South America Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 164. South America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 165. South America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 166. Brazil Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 167. Brazil Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 168. Brazil Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 169. Brazil Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 170. Argentina Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 171. Argentina Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 172. Argentina Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 173. Argentina Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 174. Rest of South America Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 175. Rest of South America Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 176. Rest of South America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 177. Rest of South America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 178. Asia Pacific Hormone Refractory Prostate Cancer, by Country USD Million (2025-2030)
  • Table 179. Asia Pacific Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 180. Asia Pacific Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 181. Asia Pacific Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 182. Asia Pacific Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 183. China Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 184. China Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 185. China Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 186. China Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 187. Japan Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 188. Japan Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 189. Japan Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 190. Japan Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 191. India Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 192. India Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 193. India Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 194. India Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 195. South Korea Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 196. South Korea Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 197. South Korea Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 198. South Korea Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 199. Taiwan Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 200. Taiwan Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 201. Taiwan Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 202. Taiwan Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 203. Australia Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 204. Australia Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 205. Australia Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 206. Australia Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 211. Europe Hormone Refractory Prostate Cancer, by Country USD Million (2025-2030)
  • Table 212. Europe Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 213. Europe Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 214. Europe Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 215. Europe Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 216. Germany Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 217. Germany Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 218. Germany Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 219. Germany Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 220. France Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 221. France Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 222. France Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 223. France Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 224. Italy Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 225. Italy Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 226. Italy Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 227. Italy Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 228. United Kingdom Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 229. United Kingdom Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 230. United Kingdom Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 231. United Kingdom Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 232. Netherlands Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 233. Netherlands Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 234. Netherlands Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 235. Netherlands Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 236. Rest of Europe Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 237. Rest of Europe Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 238. Rest of Europe Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 239. Rest of Europe Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 240. MEA Hormone Refractory Prostate Cancer, by Country USD Million (2025-2030)
  • Table 241. MEA Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 242. MEA Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 243. MEA Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 244. MEA Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 245. Middle East Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 246. Middle East Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 247. Middle East Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 248. Middle East Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 249. Africa Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 250. Africa Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 251. Africa Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 252. Africa Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 253. North America Hormone Refractory Prostate Cancer, by Country USD Million (2025-2030)
  • Table 254. North America Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 255. North America Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 256. North America Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 257. North America Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 258. United States Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 259. United States Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 260. United States Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 261. United States Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 262. Canada Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 263. Canada Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 264. Canada Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 265. Canada Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 266. Mexico Hormone Refractory Prostate Cancer, by Treatment USD Million (2025-2030)
  • Table 267. Mexico Hormone Refractory Prostate Cancer, by End-users USD Million (2025-2030)
  • Table 268. Mexico Hormone Refractory Prostate Cancer, by Distribution Channel USD Million (2025-2030)
  • Table 269. Mexico Hormone Refractory Prostate Cancer, by Diagnosis USD Million (2025-2030)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormone Refractory Prostate Cancer: by Treatment USD Million (2018-2023)
  • Figure 5. Global Hormone Refractory Prostate Cancer: by End-users USD Million (2018-2023)
  • Figure 6. Global Hormone Refractory Prostate Cancer: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Hormone Refractory Prostate Cancer: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 9. Asia Pacific Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 10. Europe Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 11. MEA Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 12. North America Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 13. Global Hormone Refractory Prostate Cancer share by Players 2023 (%)
  • Figure 14. Global Hormone Refractory Prostate Cancer share by Players (Top 3) 2023(%)
  • Figure 15. Global Hormone Refractory Prostate Cancer share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Acceleron Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Acceleron Pharma Inc. (United States) Revenue: by Geography 2023
  • Figure 21. AB Science SA (France) Revenue, Net Income and Gross profit
  • Figure 22. AB Science SA (France) Revenue: by Geography 2023
  • Figure 23. AstraZeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 27. Boston Biomedical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Boston Biomedical, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Dendreon Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Dendreon Corporation (United States) Revenue: by Geography 2023
  • Figure 31. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A (France) Revenue: by Geography 2023
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 35. Global Hormone Refractory Prostate Cancer: by Treatment USD Million (2025-2030)
  • Figure 36. Global Hormone Refractory Prostate Cancer: by End-users USD Million (2025-2030)
  • Figure 37. Global Hormone Refractory Prostate Cancer: by Distribution Channel USD Million (2025-2030)
  • Figure 38. Global Hormone Refractory Prostate Cancer: by Diagnosis USD Million (2025-2030)
  • Figure 39. South America Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 40. Asia Pacific Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 41. Europe Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 42. MEA Hormone Refractory Prostate Cancer Share (%), by Country
  • Figure 43. North America Hormone Refractory Prostate Cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Acceleron Pharma Inc. (United States)
  • AB Science SA (France)
  • AstraZeneca Plc. (United Kingdom)
  • Astellas Pharma Inc. (Japan)
  • Boston Biomedical, Inc. (United States)
  • Dendreon Corporation (United States)
  • Sanofi S.A (France)
  • Johnson & Johnson (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 181 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hormone Refractory Prostate Cancer Quantitative research analysis
Global Hormone Refractory Prostate Cancer Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Hormone Refractory Prostate Cancer Market are by end use application [].
The Hormone Refractory Prostate Cancer Market is gaining popularity and expected to see strong valuation by 2030.
  • Increased Prevalence of Prostate Cancer
  • Rise in the Number of Hospitals and Clinics

Know More About Global Hormone Refractory Prostate Cancer Report?

Have a Query? Click Here

Other Related Reports

Metastatic Uveal Melanoma Thereapeutics Comprehensive Study by Type (Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others), Application (Hospital, Clinic, Others)...
$ 3750
Brachytherapy Comprehensive Study by Type (High Dose Rate (HDR) Brachytherapy , Low Dose (LDR) Brachytherapy), Application (Prostate Cancer, Gynecological Cancer, Breast Cancer, Other Cancers), End U...
$ 3450
Q Fever Comprehensive Study by Type (Acute Q Fever, Chronic Q Fever), Treatment (Medicines (Doxycycline), Vaccination), End-users (Hospitals & Clinics, Diagnostic Centers, Surgical Centers), Diagnosi...
$ 3450
Multiple Myeloma Treatment Comprehensive Study by Application (Hospitals, Specialty Clinics, Cancer Treatment and Rehabilitation Centers, Research Organization, Laboratories), Route of Administration...
$ 3800
Mumps Virus Testing Comprehensive Study by Type (Cell Culture/Immunofluorescence, Semi-Quantitative Enzyme-Linked Immunosorbent Assay, Semi-Quantitative Chemiluminescent Immunoassay, Qualitative Real...
$ 3450
Colon Cancer Comprehensive Study by Type (Surgery, Chemotherapy, Radiation), Application (Hospitals, Ambulatory Surgical Centers, Others), Testing Techniques (Macroscopy, Microscopy, Immunochemistry,...
$ 3750